menthol has been researched along with Colitis, Mucous in 7 studies
Menthol: A monoterpene cyclohexanol produced from mint oils.
| Excerpt | Relevance | Reference |
|---|---|---|
| "This study assessed the efficacy and safety of a food supplement containing standardized menthol, limonene, and gingerol in human participants with IBS or IBS/functional dyspepsia (FD)." | 9.51 | Efficacy and safety of a food supplement with standardized menthol, limonene, and gingerol content in patients with irritable bowel syndrome: A double-blind, randomized, placebo-controlled trial. ( Beniashvili, AG; Erlykin, AG; Ivashkin, VT; Kovaleva, AL; Krasnov, GS; Kudryavtseva, AV; Mamieva, ZA; Morozova, MA; Poluektov, YM; Poluektova, EA; Shifrin, OS; Trush, EA; Ulyanin, AI, 2022) |
| "This study assessed the efficacy and safety of a food supplement containing standardized menthol, limonene, and gingerol in human participants with IBS or IBS/functional dyspepsia (FD)." | 5.51 | Efficacy and safety of a food supplement with standardized menthol, limonene, and gingerol content in patients with irritable bowel syndrome: A double-blind, randomized, placebo-controlled trial. ( Beniashvili, AG; Erlykin, AG; Ivashkin, VT; Kovaleva, AL; Krasnov, GS; Kudryavtseva, AV; Mamieva, ZA; Morozova, MA; Poluektov, YM; Poluektova, EA; Shifrin, OS; Trush, EA; Ulyanin, AI, 2022) |
| " Despite its increasing paediatric use, as in irritable bowel syndrome (IBS) treatment, the pharmacokinetics (PK) of menthol in children given PMO has not been explored." | 3.81 | Systemic exposure to menthol following administration of peppermint oil to paediatric patients. ( Abdel-Rahman, SM; Chumpitazi, BP; Garg, U; Kearns, GL; Shulman, RJ, 2015) |
| "Menthol has a half life of 3-6 h and is rapidly metabolized to menthol glucuronide which is detectable in urine and serum following menthol use." | 1.43 | Determination of Menthol in Plasma and Urine by Gas Chromatography/Mass Spectrometry (GC/MS). ( Frazee, C; Garg, U; Kearns, G; Peat, J, 2016) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (28.57) | 29.6817 |
| 2010's | 4 (57.14) | 24.3611 |
| 2020's | 1 (14.29) | 2.80 |
| Authors | Studies |
|---|---|
| Ivashkin, VT | 1 |
| Kudryavtseva, AV | 1 |
| Krasnov, GS | 1 |
| Poluektov, YM | 1 |
| Morozova, MA | 1 |
| Shifrin, OS | 1 |
| Beniashvili, AG | 1 |
| Mamieva, ZA | 1 |
| Kovaleva, AL | 1 |
| Ulyanin, AI | 1 |
| Trush, EA | 1 |
| Erlykin, AG | 1 |
| Poluektova, EA | 1 |
| Weerts, ZZRM | 1 |
| Keszthelyi, D | 1 |
| Vork, L | 1 |
| Aendekerk, NCP | 1 |
| Frijlink, HW | 1 |
| Brouwers, JRBJ | 1 |
| Neef, C | 1 |
| Jonkers, DMAE | 1 |
| Masclee, AAM | 1 |
| Kearns, GL | 1 |
| Chumpitazi, BP | 1 |
| Abdel-Rahman, SM | 1 |
| Garg, U | 2 |
| Shulman, RJ | 1 |
| Peat, J | 1 |
| Frazee, C | 1 |
| Kearns, G | 1 |
| Pilipenko, VI | 1 |
| Teplyuk, DA | 1 |
| Shakhovskaya, AK | 1 |
| Isakov, VA | 1 |
| Vorobyova, VM | 1 |
| Vorobyova, IS | 1 |
| Sarkisyan, VA | 1 |
| Kochetkova, AA | 1 |
| Mikheeva, GA | 1 |
| Yudina, AV | 1 |
| Charrois, TL | 1 |
| Hrudey, J | 1 |
| Gardiner, P | 1 |
| Vohra, S | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Efficacy and Safety of a Food Supplement With Standardized Menthol, Limonene, and Gingerol Content in Patients With Irritable Bowel Syndrome: a Double-blind, Randomized, Placebo-controlled Trial[NCT04484467] | 56 participants (Actual) | Interventional | 2018-02-09 | Completed | |||
| Peppermint Oil for the Treatment of Irritable Bowel Syndrome: Optimizing Therapeutic Strategies Using Targeted Delivery[NCT02716285] | Phase 3 | 190 participants (Actual) | Interventional | 2016-08-17 | Completed | ||
| A Randomized, Double Blind, Single Dose, Two Treatment, Two Period Crossover Pharmacokinetic Study Comparing a 182mg Colon-targeted-delivery Peppermint Oil Capsule (Tempocol-ColoPulse®) and a 182mg Enteric-coated Peppermint Oil Capsule (Tempocol®) in Heal[NCT02291445] | Phase 2 | 8 participants (Actual) | Interventional | 2015-03-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Area under the plasma concentration-time curve from t=0 hrs until t=24 hrs. (NCT02291445)
Timeframe: 24 hours
| Intervention | ug*h/L (Median) |
|---|---|
| Ileocolonic Release PO | 2331 |
| Small Intestinal Release PO | 2623 |
Menthol-glucuronide (main constituent of peppermint oil after conversion by the liver) peak plasma concentrations (NCT02291445)
Timeframe: 24 hours
| Intervention | ug/L (Median) |
|---|---|
| Ileocolonic Release PO | 563.6 |
| Small Intestinal Release PO | 702 |
Time until a measurable plasma concentration of menthol-glucuronide occurs after oral administration of peppermint oil (45ug/L) (NCT02291445)
Timeframe: 24 hours
| Intervention | minutes (Median) |
|---|---|
| Ileocolonic Release PO | 225 |
| Small Intestinal Release PO | 37 |
Time to reach maximum menthol-glucuronide (main constituent of peppermint oil after conversion by the liver) concentration in plasma (NCT02291445)
Timeframe: 24 hours
| Intervention | minutes (Median) |
|---|---|
| Ileocolonic Release PO | 360 |
| Small Intestinal Release PO | 180 |
elimination half-life; time required for the plasma concentration of menthol-glucuronide to reach half of its original value. (NCT02291445)
Timeframe: 24 hours
| Intervention | hours (Median) |
|---|---|
| Ileocolonic Release PO | 6.1 |
| Small Intestinal Release PO | 7.7 |
1 review available for menthol and Colitis, Mucous
| Article | Year |
|---|---|
Peppermint oil.
Topics: Antiemetics; Child; Female; Humans; Irritable Bowel Syndrome; Lactation; Mentha piperita; Menthol; P | 2006 |
3 trials available for menthol and Colitis, Mucous
| Article | Year |
|---|---|
Efficacy and safety of a food supplement with standardized menthol, limonene, and gingerol content in patients with irritable bowel syndrome: A double-blind, randomized, placebo-controlled trial.
Topics: Catechols; Dietary Supplements; Double-Blind Method; Dyspepsia; Fatty Alcohols; Humans; Irritable Bo | 2022 |
A Novel Ileocolonic Release Peppermint Oil Capsule for Treatment of Irritable Bowel Syndrome: A Phase I Study in Healthy Volunteers.
Topics: Abdominal Pain; Adult; Biological Availability; Capsules; Cross-Over Studies; Double-Blind Method; F | 2018 |
A Novel Ileocolonic Release Peppermint Oil Capsule for Treatment of Irritable Bowel Syndrome: A Phase I Study in Healthy Volunteers.
Topics: Abdominal Pain; Adult; Biological Availability; Capsules; Cross-Over Studies; Double-Blind Method; F | 2018 |
A Novel Ileocolonic Release Peppermint Oil Capsule for Treatment of Irritable Bowel Syndrome: A Phase I Study in Healthy Volunteers.
Topics: Abdominal Pain; Adult; Biological Availability; Capsules; Cross-Over Studies; Double-Blind Method; F | 2018 |
A Novel Ileocolonic Release Peppermint Oil Capsule for Treatment of Irritable Bowel Syndrome: A Phase I Study in Healthy Volunteers.
Topics: Abdominal Pain; Adult; Biological Availability; Capsules; Cross-Over Studies; Double-Blind Method; F | 2018 |
[Using a multicomponent functional food in IBS patients with constipation a comparative controlled study].
Topics: Adolescent; Adult; Aged; Beverages; Colonoscopy; Constipation; Female; Functional Food; Gastrointest | 2016 |
3 other studies available for menthol and Colitis, Mucous
| Article | Year |
|---|---|
Systemic exposure to menthol following administration of peppermint oil to paediatric patients.
Topics: Administration, Oral; Adolescent; Antiemetics; Area Under Curve; Child; Female; Humans; Irritable Bo | 2015 |
Determination of Menthol in Plasma and Urine by Gas Chromatography/Mass Spectrometry (GC/MS).
Topics: Antipruritics; Flavoring Agents; Gas Chromatography-Mass Spectrometry; Humans; Irritable Bowel Syndr | 2016 |
Mint conditions.
Topics: Drug Hypersensitivity; Humans; Irritable Bowel Syndrome; Mentha piperita; Menthol; Phytotherapy; Pla | 2007 |